Marketplace

TOPCON LENTIS COMFORT IOL

■ The latest addition to its Lentis line, Topcon says it has seen “unprecedented” interest in its Lentis Comfort IOL. The new multifocal lens is designed to overcome the potential drawbacks of multifocal lenses. Offering “spectacle independence,” the IOL should enable patients to drive, work at a computer and perform other everyday activities without eyeglasses.

“The feedback we’re getting from first adapters is very exciting,” Topcon sales manager Gloria McCall said in a press release. The company has noted that Brendon Moriarty, MD, a consultant ophthalmic surgeon, had Topcon Lentis Comfort IOLs implanted in both eyes.

Topcon Medical Systems Inc. www.topconmedical.com

FCI OPHTHALMICS MASTERKA

■ This monocanalicular nasolacrimal intubation stent, which recently received 510(k) clearance from the FDA, is billed as the first “pushed” stent of its kind for treating mucosal nasolacrimal stenosis in children, according to FCI Ophthalmics. This product is meant to stand in opposition to the traditional “pulled” technique that advances the stent through the nasolacrimal system and retrieves it through the nose by pulling on the guide probe or thread.

The pulled system is safer, because it does not require recovery inside the nasal cavity, and quicker, the company says. The preloaded device is made of a silicone tube with a fixation head and is pre-mounted on an introducer. The introducer is removed upon completion of intubation.

The Masterka comes in three different lengths (30, 35 or 40 mm) to account for varying patient needs.

FCI Ophthalmics www.fci-ophthalmics.com

BAUSCH + LOMB BESIVANCE

■ The FDA has granted additional labeling indications for Bausch + Lomb’s Besivance (besifloxacin) 0.6% eye drop. These include treatment of bacterial conjunctivitis caused by susceptible isolates of Pseudomonas aeruginosa. Three other ocular pathogens added to the indications granted for Besivance include Aerococcus viridians, Moraxella catarrhis and Staphylococcus warneri.

In addition, the FDA has approved B+L’s new drug application for Lotemax 0.5% gel, a topical corticosteroid formulation in its line of loteprednol ophthalmic products. Lotemax Gel is indicated for the treatment of postoperative ocular inflammation and pain following ocular surgery.

Bausch + Lomb www.bausch.com

MEDAPTUS MOBILE SCHEDULE APP

■ MedAptus’ latest app for Apple’s iPhone and iPad platform is meant to wrangle the busy physican’s schedule into manageable intervals. The app provides secure real-time schedule information for doctors moving between treatment locations.

The scheduling app’s drill-down functionality delivers information to physicians about when their patients are ready to be seen. In addition, it reveals any relevant demographic information. It also provides physicians with patients’ reasons for the office visit, their referring provider and insurance coverage.

MedAptus, Inc. www.medaptus.com

TOPCON EMR PORTAL

■ Topcon is expanding its support services by adding to its product line EMR software. In addition to EMR communication data, the software will pair with Topcon’s instrument line by providing specific information for each device including sample data.

Topcon Medical Systems Inc. www.topconmedical.com

DIOPSYS CORDA SOFTWARE

■ Diopsys is aiming to improve the analysis of optical coherence tomography images. Its CORDA software uses existing images to help in the assessment of the retinal nerve fiber layer (RNFL). Analysis of RFNL thickness, the company says, is being overstated due to current OCT technology limitations. The CORDA software is available in December.

Diopsys Inc. www.diopsys.com